Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00148369
Status:
COMPLETED
Last Update Posted:
2010-02-19
First Post:
2005-09-06
Brief Title:
A Multi-Center Observational Safety Registry of Subjects With Idiopathic Parkinsons Disease Previously Treated With Intraputaminal Infusion of Liatermin
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Multi-Center Observational Safety Registry of Subjects With Idiopathic Parkinsons Disease Previously Treated With Intraputaminal Infusion of Liatermin
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to evaluate clinical and serologic outcomes after the discontinuation of liatermin therapy as assessed by development of new clinical conditions beyond those expected in patients with advancing Parkinsons disease In addition the development or resolution of anti-r-metHuGDNF binding and neutralizing antibodies will be monitored
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None